Get the Stockscreener App
182.91
0.30%
-0.55
After Hours:
182.91
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $182.91, with a volume of 454.07K.
It is down -0.30% in the last 24 hours and up +2.37% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$183.46
Open:
$183.24
24h Volume:
454.07K
Relative Volume:
0.48
Market Cap:
$20.45B
Revenue:
$9.54B
Net Income/Loss:
$841.00M
P/E Ratio:
24.58
EPS:
7.44
Net Cash Flow:
$1.02B
1W Performance:
-0.32%
1M Performance:
+2.37%
6M Performance:
+9.91%
1Y Performance:
+18.19%
1-Day Range:
$182.50
$185.05
1-Week Range:
$179.77
$185.05
52-Week Range:
$146.17
$185.62
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
182.91 | 20.14B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
State of Wyoming Lowers Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Teewinot Capital Advisers L.L.C. Takes $2.14 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
1,700 Shares in Quest Diagnostics Incorporated $DGX Purchased by Ransom Advisory Ltd - MarketBeat
Ascent Group LLC Buys Shares of 9,285 Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Holdings Boosted by Fred Alger Management LLC - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
Sandler Capital Management Buys Shares of 19,993 Quest Diagnostics Incorporated $DGX - MarketBeat
Cinctive Capital Management LP Sells 82,768 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Amundi Sells 215,132 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Baird Financial Group Inc. Reduces Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Adage Capital Partners GP L.L.C. Has $12.29 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Game Plan Financial Advisors LLC Acquires Shares of 9,522 Quest Diagnostics Incorporated $DGX - MarketBeat
Woodline Partners LP Has $64.41 Million Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
MBB Public Markets I LLC Acquires Shares of 1,909 Quest Diagnostics Incorporated $DGX - MarketBeat
13,892 Shares in Quest Diagnostics Incorporated $DGX Bought by Caxton Associates LLP - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Advisors Asset Management Inc. Sells 7,953 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Transcript : Quest Diagnostics Incorporated Presents at Baird Global Healthcare Conference 2025, Sep-10-2025 10 - MarketScreener
Canada Post Corp Registered Pension Plan Raises Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Royal Bank of Canada Purchases 172,518 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Alliancebernstein L.P. Increases Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated Crosses 200 Day MA — Signal or NoiseWeekly Trade Report & High Conviction Trade Alerts - beatles.ru
Quest Diagnostics Incorporated Shows Early Signs of Technical Strength2025 EndofYear Setup & Smart Money Movement Alerts - beatles.ru
Quest Diagnostics says it's tracking a concerning drug trend in the workplace - Scripps News
Sentiment analysis tools applied to Quest Diagnostics IncorporatedJuly 2025 PostEarnings & Advanced Swing Trade Entry Plans - Newser
1,993 Shares in Quest Diagnostics Incorporated $DGX Bought by Paloma Partners Management Co - MarketBeat
Should you wait for a breakout in Quest Diagnostics IncorporatedPortfolio Update Summary & Capital Efficiency Focused Strategies - Newser
What are the future prospects of Quest Diagnostics IncorporatedBreakout Watch & Consistent Return Strategy Ideas - خودرو بانک
8 Knots Management LLC Makes New $20.91 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Is There Enough Volume to Lift Quest Diagnostics IncorporatedJuly 2025 Closing Moves & AI Enhanced Execution Alerts - beatles.ru
Is Quest Diagnostics Incorporated still worth holding after the dipJuly 2025 Levels & Weekly Momentum Stock Picks - Newser
A Study Finds More Fentanyl Showing Up in Workplace Drug Tests. Here's What to Do About It - Inc.com
Stock Analysis | Quest Diagnostics OutlookTechnical Weakness and Mixed Analyst Signals - AInvest
Pattern recognition hints at Quest Diagnostics Incorporated upsidePortfolio Growth Summary & Real-Time Buy Signal Alerts - Newser
Quest Diagnostics and the Future of Precision Medicine: Strategic Positioning in the Growing Pharmacogenomics Market - AInvest
Published on: 2025-09-05 02:16:44 - Newser
Rafferty Asset Management LLC Has $1.74 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Order flow analysis tools used on Quest Diagnostics IncorporatedInflation Watch & Low Volatility Stock Recommendations - Newser
How to use a screener to detect Quest Diagnostics Incorporated breakoutsRecession Risk & Accurate Buy Signal Notifications - Newser
Multi asset correlation models including Quest Diagnostics IncorporatedWeekly Market Report & Daily Technical Forecast Reports - Newser
Should I average down on Quest Diagnostics Incorporated stockJuly 2025 Spike Watch & Capital Efficient Trade Techniques - خودرو بانک
Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering - MarketScreener
Revolutionary 17-Gene Test: Quest Diagnostics Launches PGx Service to Transform Drug Prescriptions - Stock Titan
Analyzing net buyer seller activity in Quest Diagnostics IncorporatedWeekly Risk Report & Advanced Swing Trade Entry Plans - Newser
Applying big data sentiment scoring on Quest Diagnostics IncorporatedWeekly Profit Analysis & AI Based Trade Execution Alerts - Newser
Is Quest Diagnostics Incorporated stock bottoming outPortfolio Performance Report & Weekly Breakout Stock Alerts - Newser
What to do if you’re stuck in Quest Diagnostics IncorporatedVolume Spike & Daily Growth Stock Tips - Newser
Can Quest Diagnostics Incorporated reach resistance levels soonMarket Movement Recap & Daily Entry Point Trade Alerts - خودرو بانک
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):